Colorectal Cancer Screening saves lives - Gallipolis Daily Tribune mydailytribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mydailytribune.com Daily Mail and Mail on Sunday newspapers.
Tuesday, March 2, 2021
On February 26, 2021, the Departments of Labor, Health and Human Services (HHS), and the Treasury issued Frequently Asked Questions (FAQs) on the implementation of the Families First Coronavirus Response Act (“FFCRA”), the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), and other health coverage issuesrelated to COVID-19.
COVID-19 Diagnostic Testing
FFCRA requires group health plans and health insurance issuers offering group or individual health insurance coverage, including grandfathered health plans (collectively, “Plans”) to cover certain items and services related to the testing and diagnosis of COVID-19 without cost-sharing, prior authorization, or other medical management requirements. The CARES Act expanded the range of diagnostic items and services that Plans must cover. The CARES Act also requires Plans to reimburse any provider of COVID-19 diagnostic testing at an amount that equals the negotiated
Ibram X. Kendi is featured speaker in forum on his experience with colon cancer and its impact on his groundbreaking work on antiracism Launch of "Gut.
(1)
Median is building a cloud based end-to-end approach performing both localization and discrimination of malignant and benign lung lesions.
The company plans to demonstrate the potential of deep learning models to increase the accuracy, consistency and adoption of lung cancer screening worldwide.
First results for a proof of concept on a cohort of 1,800 patients are expected in H2, 2021.
Regulatory News:
Median Technologies (ALMDT:PA) (Paris:ALMDT) unveils today a new iBiopsy Clinical Development Plan (CDP) for the diagnosis of early-stage lung cancer in high-risk populations based on Low Dose Computed Tomography (LDCT) scans, strengthening its positioning in early-stage diagnosis, such as early-stage liver cancer diagnosis and non-alcoholic steatohepatitis (NASH) identification.